Aurinia Settles Teva Patent Litigation, Secures LUPKYNIS Exclusivity Until December 2036
AUPH sits 58% above its 52-week low of $10.34.
Summary
Aurinia settled patent litigation with Teva, delaying generic competition for LUPKYNIS until at least December 2036 and validating its core patents.
Key Events · Legal and Risk Events · AUPH
-
Teva Settlement Secures Exclusivity
Teva stipulated that Aurinia's U.S. Patent Nos. 10,286,036 and 11,622,991 are valid, enforceable, and infringed, and may not launch generic voclosporin before December 7, 2036.
-
LUPKYNIS Revenue Protected
The settlement removes a near-term generic threat to LUPKYNIS, which generated $79.4M in Q2 2026 net product sales, preserving a key revenue stream through 2036.
-
Ongoing Litigation Against Other Generics
Aurinia's patent infringement actions continue against DifGen, Dr. Reddy's, Hikma, Lotus/Sandoz, and Zydus in the District of New Jersey, with the Teva outcome likely strengthening Aurinia's position.
-
Patent Expiry in December 2037
The settlement aligns with the December 2037 expiry of the asserted patents, effectively providing market exclusivity for the full remaining patent term.
Analysis · AUPH · Life Sciences
Aurinia resolved the Teva patent challenge with a settlement that keeps generic voclosporin off the U.S. market until at least December 7, 2036. Teva stipulated that Aurinia's key patents are valid and infringed, removing a major overhang on LUPKYNIS revenue. The company still faces ongoing litigation against five other generic filers, but this settlement establishes a strong precedent and extends the revenue runway for its flagship product.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUPH was trading at $16.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.34 to $19.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.